Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc (DMAC) is a clinical-stage biopharmaceutical company advancing novel therapies for neurological disorders and chronic kidney disease. This page serves as the definitive source for DMAC-related news, providing investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access the latest press releases detailing progress on DM199 – the company's recombinant human tissue kallikrein-1 therapy – along with strategic partnerships and peer-reviewed research findings. Our curated news collection covers essential updates including trial results, FDA communications, and scientific presentations, helping stakeholders track the company's progress in addressing unmet medical needs.
Key focus areas include advancements in acute ischemic stroke treatments and chronic kidney disease management. Bookmark this page for streamlined access to earnings reports, investor conference materials, and analysis of DMAC's position within the competitive biopharmaceutical landscape. All content is maintained to reflect the most current and relevant information for informed decision-making.
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported its second quarter 2021 financial results, highlighting progress in its clinical trials for DM199. The FDA accepted the IND application for a pivotal Phase 2/3 trial aimed at stroke recurrence prevention, with a projected initiation by summer 2021. Interim results from the REDUX trial showed a 33% reduction in UACR in patients with IgA Nephropathy. Despite increased R&D expenses totaling $2.2 million, cash reserves stand at $21.3 million. The company is addressing slower enrollment in clinical trials due to COVID-19 concerns.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its Q2 2021 financial results post-market on August 11, with a live conference call scheduled for August 12 at 7:00 AM CT. The call aims to provide updates on business developments and financial outcomes. DiaMedica focuses on innovative treatments for neurological disorders and kidney diseases, specifically advancing its lead candidate DM199 in clinical trials for acute ischemic stroke and chronic kidney disease.
DiaMedica Therapeutics (Nasdaq: DMAC) announces that President and CEO Rick Pauls will meet with investors and participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 10:00 am ET. Pauls aims to discuss DiaMedica’s clinical development programs and business strategy. The company is focused on developing treatments for neurological disorders and kidney diseases, particularly through its lead candidate, DM199, which is in Phase 2/3 trials for acute ischemic stroke and a Phase 2 trial for chronic kidney disease.
DiaMedica Therapeutics (Nasdaq: DMAC) announced the election of Amy Burroughs and Dr. Charles Semba to its Board of Directors. Burroughs, currently President and CEO of Cleave Therapeutics, brings over 20 years of experience in commercial development and strategy. Dr. Semba, Chief Medical Officer at Eluminex Biosciences, has extensive drug development experience and has led key approvals including LUCENTIS and XIIDRA. Their expertise is expected to enhance DiaMedica's advancement of DM199 in pivotal trials for acute ischemic stroke and chronic kidney disease.
DiaMedica Therapeutics (Nasdaq: DMAC) announced positive interim results from its Phase 2 REDUX trial for DM199 in chronic kidney disease (CKD). The trial studied three cohorts with notable improvements in kidney function and blood pressure. Key findings include a 27% reduction in urine albumin-to-creatinine ratio (UACR) and a 2 ml/min increase in estimated glomerular filtration rate (eGFR) in African Americans. In IgA Nephropathy patients, UACR decreased by 33%. DM199 was well tolerated, with no severe adverse events reported. DiaMedica plans to advance into pivotal trials for acute ischemic stroke.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the FDA's acceptance of its IND application for DM199, targeting Acute Ischemic Stroke (AIS). The ReMEDy2 Trial, a pivotal Phase 2/3 study, will assess DM199’s efficacy in improving outcomes for AIS patients lacking other treatment options. Following a Phase 2 study showing improved stroke outcomes and safety, the trial anticipates enrolling about 350 participants across 75 sites. The trial aims to restore low KLK1 levels, potentially reducing stroke recurrence and enhancing recovery, addressing a significant unmet medical need.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) provided a business update and financial results for Q1 2021, emphasizing its ongoing clinical trials for DM199.
The company submitted an IND application for a Phase 2/3 trial of DM199 targeting acute ischemic stroke, expecting FDA review completion by mid-May 2021.
Despite slower enrollment in ongoing studies due to COVID-19, preliminary results from the chronic kidney disease cohort are anticipated in Q2 2021. Q1 2021 R&D expenses rose to $2.4 million from $1.4 million year-over-year, while cash reserves stood at $23.4 million.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its first quarter 2021 financial results after markets close on May 5th. A live conference call is scheduled for May 6th at 7:00 AM CT to discuss the financial results and provide a business update. Interested participants can join via phone or through a webcast, which will also be available for playback on the company's website for 12 months. A telephonic replay will be accessible until May 13, 2021. For further details, visit www.diamedica.com.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that President and CEO Rick Pauls will present at the B. Riley Neuroscience Investor Conference on April 29th at 11:30am ET. The company will also be available for one-on-one meetings at the event, with investors encouraged to schedule these through B. Riley. The recorded presentation will be accessible on DiaMedica’s website starting April 29th.
DiaMedica focuses on developing treatments for neurological disorders and kidney diseases, aiming to enhance patient quality of life.
DiaMedica Therapeutics (Nasdaq: DMAC) announced its participation in the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings, conducted virtually from April 6-10, 2021. The company will present two abstracts: the REDUX Study on DM199 for chronic kidney disease and a study on KLK1 levels in kidney patients. These abstracts will be available through the NKF mobile app and DiaMedica's website post-event. DM199 is a recombinant form of human tissue kallikrein-1, currently under investigation for its effectiveness in treating neurological and kidney disorders.
FAQ
What is the current stock price of Diamedica Therapeutics (DMAC)?
What is the market cap of Diamedica Therapeutics (DMAC)?
